


VIA FIRST CLASS MAIL

I hereby certify that this paper is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to the U.S. Patent and Trademark Office on March 2, 2001.

FULBRIGHT & JAWORSKI

Annette Grossman

GP 1642
4/11/01
Dk
LUD 5538.1CIP - JEL/NDH (987339)
3/13/01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 13 2001

Applicant(s) : CHEN et al.
Serial No. : 09/270,437
Filing Date : March 16, 1999
For : ISOLATED NUCLEIC ACID MOLECULE ENCODING CANCER ASSOCIATED ANTIGENS, THE ANTIGENS PER SE, AND USES THEREOF
Art Unit : 1642
Examiner : K. Canella

TECH CENTER 1600/2900

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

March 2, 2001

**RESPONSE
TO RESTRICTION
REQUIREMENT**

SIR:

In response to the restriction requirement of February 13, 2001, applicants elect Group I, claims 53-73, 80-84, 108 & 109 with traverse. It is believed that claims 92-95 and 102-104 (Group V) should be included.

The claims of group V specifically require the use of the products of Group I, so there will inevitably be a search of "V" in searching "I". Further, the examiner's assertion that the nucleic acid molecules of Group I "can be used in an in vitro mutagenesis assay" receives no support from the record, or the art.

LUD 5538.1CIP - JEL/NDH (987339)

In view of the forgoing, withdrawal of the restriction between Groups I and V is believed proper and is urged.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By

Norman D. Hanson

Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000